| Literature DB >> 30425759 |
Hiroaki Yanagawa1, Hiroshi Nokihara1, Hideto Yokoi2, Hitoshi Houchi2, Masahiro Nagai3, Risako Yamashita3, Narufumi Suganuma4, Masamitsu Hyodo4.
Abstract
BACKGROUND: The new Clinical Trials Act that recently came into effect in Japan emphasizes the reliability of investigator-initiated clinical trials. Although Japanese clinical research coordinators have been mainly engaged in operational roles in industry-initiated clinical trials for drug approval (registration trials), broadening their contribution to cover more types of clinical research may lead to quality improvement of clinical research. To ultimately establish a clinical research infrastructure that meets the needs of the new era of Clinical Trials Act, here we gathered basic information on how clinical research coordinators might make such contributions.Entities:
Keywords: Clinical Trials Act; Clinical research; Clinical research coordinators; Japan; Perspective; Quality assurance; Role
Year: 2018 PMID: 30425759 PMCID: PMC6225862 DOI: 10.14740/jocmr3602w
Source DB: PubMed Journal: J Clin Med Res ISSN: 1918-3003
Respondent Characteristics
| Number (%) | |
|---|---|
| Respondents (n = 69) | |
| Gender | |
| Male | 11 (15.9) |
| Female | 58 (84.1) |
| Age | |
| 20 - 29 | 8 (11.6) |
| 30 - 39 | 24 (34.8) |
| 40 - 49 | 20 (29.0) |
| > 50 | 17 (24.6) |
| Basic qualifications | |
| Medical doctor | 4 (5.8) |
| Pharmacist | 7 (10.1) |
| Nurse | 26 (37.7) |
| Medical technologist | 14 (20.3) |
| Clinical nutritionist | 4 (5.8) |
| No medical qualifications | 14 (20.3) |
| Affiliations | |
| Medical institution | 50 (72.5) |
| Contract research organization | 1 (1.4) |
| Site management organization | 18 (26.1) |
| Pharmaceutical company | 0 |
| Others | 0 |
Field and Total Length of Main Engagement
| Number (%) | |
|---|---|
| Respondents (n = 69) | |
| Field of main engagement | |
| Support and management | 68 (98.6) |
| Investigator of registration trials | 1 (1.4) |
| Investigator of clinical research | 0 |
| Not involved | 0 |
| Others | 0 |
| Total length of main engagement | |
| < 6 months | 8 (11.6) |
| 6 - 12 months | 2 (2.9) |
| 1 - 5 years | 31 (44.9) |
| ≥ 5 years | 28 (40.6) |
Main Area and Roles of Involvement
| Number (%) | |
|---|---|
| Respondents (n = 69) | |
| Main area of involvement | |
| Industry-initiated registration trials | 48 (69.7) |
| Investigator-initiated registration trials | 1 (1.4) |
| Industry-initiated clinical research | 5 (7.2) |
| Investigator-initiated clinical research | 10 (14.5) |
| Others | 0 |
| No response | 5 (7.2) |
| Main roles of involvement | |
| Conventional activities of a CRC in registration trials | 41 (59.5) |
| Ethics committee support | 17 (24.7) |
| Study planning and/or biostatistics | 1 (1.4) |
| Project management | 1 (1.4) |
| Data management | 2 (2.9) |
| Monitoring and auditing | 2 (2.9) |
| Others | 0 |
| No response | 5 (7.2) |
Perspectives of the Two Groups of Respondents - CRCs and Others - on CRC Involvement as Professionals in Clinical Research Beyond Their Conventional Activity in Industry-Initiated Registration Trials
| Number (%) | |||
|---|---|---|---|
| CRCs* (n = 41) | Others* (n = 28) | Total (n = 69) | |
| Strongly agree | 9 (22.0) | 8 (28.6) | 17 (24.6) |
| Agree | 11 (26.8) | 5 (17.9) | 16 (23.2) |
| Neutral | 7 (17.1) | 9 (32.0) | 16 (23.2) |
| Disagree | 11 (26.8) | 4 (14.3) | 15 (21.7) |
| Strongly disagree | 3 (7.3) | 1 (3.6) | 4 (5.8) |
| No response | 0 | 1 (3.6) | 1 (1.4) |
“CRCs” and “Others” are designated as those who answered conventional activities of a CRC in registration trials as their main roles, and as those who provided other answers in question Part 2, No. 5, respectively.